{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:48:33Z","timestamp":1793490513313,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jchf.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T21:36:13Z","timestamp":1625693773000},"page":"627-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Integrating High-Sensitivity Troponin T and\u00a0Sacubitril\/Valsartan Treatment in\u00a0HFpEF"],"prefix":"10.1016","volume":"9","author":[{"given":"Mauro","family":"Gori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret F.","family":"Prescott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"Van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lefkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"376","key":"10.1016\/j.jchf.2021.04.009_bib1","first-page":"897","article-title":"Heart failure with preserved ejection fraction","volume":"2","author":"Redfield","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.jchf.2021.04.009_bib2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.04.009_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2021.04.009_bib4","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/eurheartj\/ehu204","article-title":"New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes","volume":"35","author":"Senni","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2021.04.009_bib5","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.04.009_bib6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"14","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.04.009_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.04.009_bib8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/CIRCULATIONAHA.117.027681","article-title":"High-sensitive cardiac troponin for prediction of clinical heart failure: are we ready for prime time?","volume":"135","author":"Gori","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.04.009_bib9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2337\/dc15-1760","article-title":"Natriuretic peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: the Atherosclerosis Risk In Communities (ARIC) study","volume":"39","author":"Gori","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2021.04.009_bib10","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehs191","article-title":"Troponin elevation in patients with heart failure, on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart\u00a0Failure Section","volume":"33","author":"Januzzi","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2021.04.009_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamacardio.2016.4726","article-title":"Factors associated with and prognostic implications of cardiac troponin elevation in decompensated heart failure with preserved ejection fraction: findings from the American Heart Association Get With The Guidelines-Heart Failure Program","volume":"2","author":"Pandey","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2021.04.009_bib12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCHEARTFAILURE.114.001427","article-title":"Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696","volume":"7","author":"Jhund","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2021.04.009_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005312","article-title":"cardiac troponin i and risk of cardiac events in patients with heart failure and preserved ejection fraction","volume":"11","author":"Myhre","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2021.04.009_bib14","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ejhf.911","article-title":"The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction","volume":"19","author":"Gohar","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.04.009_bib15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12265-015-9618-4","article-title":"Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure","volume":"8","author":"Motiwala","year":"2015","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jchf.2021.04.009_bib16","first-page":"65","article-title":"Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure","volume":"2","author":"Gaggin","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.04.009_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijcard.2017.01.021","article-title":"Prognostic significance of serial high-sensitivity troponin I measurements following acute cardiac decompensation-correlation with longer-term clinical outcomes and reverse remodelling","volume":"232","author":"Wallenborn","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2021.04.009_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ejhf.1359","article-title":"The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes","volume":"21","author":"R\u00f8rth","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.04.009_bib19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2021.04.009_bib20","first-page":"471","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.04.009_bib21","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cca.2010.12.034","article-title":"Multicenter analytical evaluation of a high-sensitivity troponin T assay","volume":"412","author":"Saenger","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jchf.2021.04.009_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of\u00a0recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J\u00a0R Stat Soc B"},{"key":"10.1016\/j.jchf.2021.04.009_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.04.009_bib24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.117.031560","article-title":"prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis","volume":"137","author":"Aimo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.04.009_bib25","article-title":"highly sensitive cardiac troponins: the evidence behind sex-specific cutoffs","volume":"9","author":"Bhatia","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2021.04.009_bib26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjcard.2013.04.060","article-title":"Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy","volume":"112","author":"Kawasaki","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2021.04.009_bib27","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2021.04.009_bib28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/eurheartj\/ehx721","article-title":"Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction","volume":"39","author":"Taqueti","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2021.04.009_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacc.2018.04.039","article-title":"myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction","volume":"72","author":"Obokata","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.04.009_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijcard.2018.06.060","article-title":"Sacubitril\/valsartan therapeutic strategy in HFpEF: clinical insights and perspectives","volume":"281","author":"Gori","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2021.04.009_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2016.06.083","article-title":"Angiotensin receptor-neprilysin inhibitor (ARNi): clinical studies on a new class of drugs","volume":"226","author":"Gori","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2021.04.009_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.04.009_bib33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2021.04.009_bib34","first-page":"241","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.04.009_bib35","first-page":"372","article-title":"Effects of sacubitril\/valsartan on N-terminal pro-b-type natriuretic peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.04.009_bib36","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ejhf.1961","article-title":"Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities","volume":"22","author":"Quarta","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.04.009_bib37","first-page":"102","article-title":"Haemodynamics of heart failure with preserved ejection fraction: a clinical perspective","volume":"2","author":"Gori","year":"2016","journal-title":"Card Fail Rev"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921002183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921002183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T09:27:46Z","timestamp":1718789266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177921002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2213177921002183"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2021.04.009","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating High-Sensitivity Troponin T and\u00a0Sacubitril\/Valsartan Treatment in\u00a0HFpEF","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}